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METHODS: The analysis consisted of: 1) a comparison of the
annual drug costs and percent LDL cholesterol (LDL-C) reduc-
tion for E/S and all statins/all doses; and 2) a model of a hypo-
thetical population of 1000 untreated coronary heart disease
(CHD) patients prescribed either E/S 10/20 or usual care with
statin monotherapy for ﬁve years. The model examined the cost
offsets or savings for E/S 10/20 compared to usual care, esti-
mated on a per patient basis due to projected differences in car-
diovascular disease (CVD) related hospitalization costs plus drug
costs (wholesale acquisition costs or WAC). Sensitivity analyses
included comparing E/S 10/20 with atorvastatin, and varying
drug acquisition costs. Key parameters of the model were as
follows: Usual care was assumed to provide LDL-C reduction
based upon the market-share weighted average of the reported
efﬁcacy for each statin. A log-linear regression based on end-
point trials estimated the relationship between LDL-C and CVD
event rates. The cost per patient with an event was estimated to
be $22,430 based upon analysis of CVD hospitalizations in
managed care claims. RESULTS: First, based upon WAC, the
annual drug cost per person for E/S was calculated as $842. For
high-efﬁcacy statins/doses (>40% LDL-C reduction), the annual
drug costs per person were $1080 (atorvastatin), $1379 (sim-
vastatin), and $803 (rosuvastatin). Second, compared to usual
care for ﬁve years of treatment, E/S 10/20 was estimated to result
in cost savings of $1568 per patient. Sensitivity analyses con-
ducted also showed cost savings for E/S. CONCLUSION: Com-
pared to usual care with statin monotherapy, treatment with E/S
10/20 was estimated to reduce CVD events and hospitalizations
among untreated CHD patients. This is projected to result in cost
savings over ﬁve years.
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OBJECTIVES: The purpose of this research is to estimate ator-
vastatin, simvastatin and pravastatin incremental cost-utility
ratios in Mexican patients with hypercholesterolemia in sec-
ondary prevention and ages between 45–70 years. METHODS:
A Markov model was used with ﬁve ﬁnal outcomes: angina pec-
toris (AP), myocardial infarction (MI), cerebrovascular disease
(CVD), absence of cardiovascular events and death. The follow
up period was ﬁve years, applying a 5% cost-utility discount
rate. The perspective was that of the National Health System
(only direct medical costs). The utility measure was obtained by
applying a survey to Mexican cardiologists with clinical experi-
ence and with the aid of survival tables published in the litera-
ture. The quality-adjusted life-years (QALYs) were constructed
for each ﬁnal outcome. Cost per event was obtained by review-
ing patient clinical records and expert opinion. The sensitivity
analysis was univariate and probabilistic and acceptability curves
were constructed. RESULTS: Annual average medical care costs
per event were: US$9906 for AP, US$8510 for MI, US$4720 for
CVD, US$2093 in the absence of cardiovascular events, and
US$13,744 in the case of death. The quality-adjusted life years
for MI were 1.2 years, for AP 2.9 years, for CVD 1.0 years, in
the absence of cardiovascular events 4.4 years, and in case of
death 0.0 years. For atorvastatin, the expected cost for treatment
during the follow up period was US$10,713, for simvastatin
US$15,873 and for pravastatin US$14,193. Finally, QALYs 
for atorvastatin, simvastatin and pravastatin during that same
period were 3.8; 3.5 and 3.7 years, respectively. CONCLU-
SIONS: Atorvastatin turned out to be dominant in Mexico and
offered the treatment with more cost-utility for patients with
hypercholesterolemia in secondary prevention, followed by
pravastatin and simvastatin. Stochastic sensitivity analysis
showed the same results.
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OBJECTIVES: This study assessed the predictors of compliance
and persistence to statin therapy among Texas Medicaid patients.
METHODS: A retrospective cohort-analysis using pharmacy
and medical claims of new statin users between September 1,
1999–August 31, 2001 was done. Compliance was assessed
using medication possession ratio (MPR), which is a ratio of the
sum of the days’ supply (except on the last prescription reﬁll
date) to the total number of days between the ﬁrst and last 
prescription reﬁll date. Persistence was deﬁned as the time to
therapy discontinuation or the failure to reﬁll a prescription
within 60 days of exhausting the last supply. The predictors of
compliance and persistence that were assessed included gender,
age, ethnicity, presence of disease conditions, and total number
of prescriptions other than statins. Logistic regression and Cox
regression models were used to assess the predictors. RESULTS:
Of the total (N = 7440) patients, 65.2% were females and the
mean age was 49.7 years (S.D. = 9.4 years). White, non-Hispanic
(42.7%), Hispanic (32.7%), and Black, non-Hispanic (22.5%)
formed the majority of the ethnic categories. The mean MPR was
0.7 (S.D. = 0.2) and 56.7% of the patients had an MPR of less
than 0.8. At the end of 310 days, only 50% of the patients were
still persistent with their therapy. The cumulative probability of
being persistent to therapy at the end of the 2-year period was
0.41. The predictors of improved compliance and persistence to
statin therapy were male gender, being non-Hispanic white, and
absence of disease conditions such as CHD, diabetes, and hyper-
tension. CONCLUSIONS: Adherence to statin therapy is sub-
optimal. There exists a gender gap as well as ethnic disparity
with regards to adherence. Steps need to be taken to promote
adherence in order to reduce the risk and the long-term costs
associated with CHD.
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OBJECTIVES: To determine how switching to a new statin after
treatment initiation affects new statin users’ compliance and per-
sistence, and to evaluate switching rates among ﬁve statins: ator-
vastatin, ﬂuvastatin, lovastatin, pravastatin, and simvastatin.
METHODS: The sample includes 24,035 patients over the 
age of 18 who were continuously eligible for two-years. These
patients are all new statin users as deﬁned by a one-year wash-
out period before the ﬁrst statin prescription. Patients with only
one claim or with claims covering more than 30 days of supply
were excluded. Their compliance is measured with the medica-
tion possession ration (MPR) and their persistence with the 
duration of continuous therapy. Logistic regression (simple or
weighed with propensity score for drug treatment assignment)
was used for compliance and censored regression for persistence.
RESULTS: Switching negatively impacts persistence (-14.5%
duration of continuous therapy) vs. no switch (p < 0.0001). The
